Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial...

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• ST-segment-elevation myocardial infarction (STEMI) triggers a significant inflammatory response, increasing heart failure risk.
• Interleukin-1 (IL-1) plays a key role in the acute inflammatory process post-STEMI.

Purpose of the Study:

• To evaluate the efficacy of IL-1 blockade with anakinra in reducing systemic inflammation (hsCRP levels) in STEMI patients.
• To assess the impact of anakinra on cardiac remodeling and clinical outcomes, including heart failure and mortality.

Main Methods:

• A randomized, double-blind, placebo-controlled trial (VCUART3) involving 99 STEMI patients.
• Patients received anakinra (once or twice daily) or placebo for two weeks.
• Key endpoints included hsCRP levels, left ventricular volumes, ejection fraction, and clinical events (death, heart failure, hospitalization).

Main Results:

• Anakinra significantly reduced hsCRP area under the curve compared to placebo (P<0.001).
• No significant differences in left ventricular remodeling (end-systolic volume, ejection fraction) were observed at 12 months.
• Anakinra significantly decreased the incidence of death or new-onset heart failure (P=0.046) and death/hospitalization for heart failure (P=0.011).
• Serious infection rates were similar between groups; injection site reactions were more frequent with anakinra.

Conclusions:

• IL-1 blockade with anakinra effectively reduces the acute inflammatory response in STEMI patients.
• Anakinra shows a significant benefit in reducing major adverse cardiovascular events, specifically heart failure and mortality, post-STEMI.
• While generally well-tolerated, anakinra is associated with increased injection site reactions.